FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology and immunology. Proposed here is a polynucleotide, encoding a cyclic single-stranded tri-specific antibody. The antibody is directed against human ovarian carcinoma in vitro, has mass of approximately 84 kD and consists of three components: an antibody against human ovarian carcinoma cells, anti-CD3 antibody and anti-CD28 antibody, which are joined together by peptide interlinks such that, they form a cyclic antibody. Invented is an expression vector, containing a coding polynucleotide and versions of E.coli host cell based on the polynucleotide and expression vector.
EFFECT: use of the invention provides for a stable antibody molecule, optimum for activation of T-cells, which can be used in curing human ovarian carcinoma.
8 cl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT SINGLE-STRAND TRISPECIFIC ANTIBODY ANTI-CEA/CD3/CD28, PRODUCED THROUGH GENETIC ENGINEERING | 2005 |
|
RU2361878C2 |
| TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF | 2016 |
|
RU2730605C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| SILENT ANTI-CD28-ANTIBODY AND THEIR APPLYING | 2001 |
|
RU2261723C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
